IDH1 and cancer: The low frequencies of IDH1 and IDH2 mutations in human cancer were confirmed with MSK_Impact; the overall frequencies of IDH1 and IDH2 alterations were 3% and <1%, respectively; and IDH1 and IDH2 hotspot mutations were 2% and 0.3% (or 260 and 31), respectively (Figure 1; Table 1 and Table S1).